BeyondSpring Inc. Aktie

Good morning, and welcome to the 2026 Annual Meeting of Shareholders of BeyondSpring Inc.

Good morning. I'm Min Qiu, Chief Executive Officer of BeyondSpring Inc. It's my pleasure to preside over our company's 2026 Annual Meeting. This meeting is officially called to order. I'd like to thank Richard Ouyang from our independent auditor, CBIZ, who is in attendance at today's meeting. A notice of the meeting was sent to all shareholders of record as of the close of business on September 3, 2026. Only shareholders of record are entitled to vote. I'm informed by our Inspector of Election that the holders of more than a majority of the total number of outstanding shares of common share entitled to vote are present, either virtually or by proxy. So a quorum is present. The polls are open for voting through the web portal. Shareholders who would like to vote may do so now and follow the instructions there. The polls will be closed following the discussion of today's business items.

The first and only item is the ratification of the appointment of CBIZ as our independent registered public accounting firm for the fiscal year ending December 31, 2026. Our Board recommended that our shareholders vote for the ratification of authority. If a shareholder would like to make a comment regarding the proposal, please submit your comments through the web portal.

There is no further discussion regarding the proposals. We will now proceed to vote. Any shareholders still wishing to vote should do so now. If you have already sent in your proxy or voted via telephone or Internet and do not want to change your vote, you do not need to take any further action. I will pause for a moment for any final voting.

[Voting]

Now that everyone has had the opportunity to vote, I now declare the polls closed. I can now present the voting results received from our Inspector of Election. I'm pleased to report that the majority of votes cast have been voted in favor of the ratification appointment of CBIZ as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

We greatly value shareholder input. Any questions submitted will be carefully reviewed and addressed after the meeting through our transfer agent. Complete voting results will be filed with the Form 8-K that will be posted on the sec.gov website, following the tabulation of the final voting results.

That concludes the business items for consideration at today's meeting. Thank you for your participation. The meeting is now adjourned.

The meeting has now concluded. Thank you for joining. You may now disconnect.

Greetings. Welcome to BeyondSpring's Corporate Update and Strategic Development Call. [Operator Instructions] Please note that this conference is being recorded. At this time, I'll now turn the conference over to Min Qiu, CEO of BeyondSpring. Thank you. You may now begin.

Good morning, everyone, and thank you for joining today's call. Before we begin, I would like to remind listeners that remarks made on today's call may reflect forward-looking statements that are related to such matters as BeyondSpring's clinical and preclinical research and development activities and results, regulatory and commercial plans, industry trends, market potential, collaborative initiatives and financial projections, among others.

While management believes that its assumptions, expectations and projections are reasonable in view of the currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this call for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's 10-K and other filings with the SEC, which are available on the Investors section of BeyondSpring's website.

Joining me today are our Chairman, Dr. Lan Huang, our Chief Executive Officer, Mr. Min Qiu; and our Chief Scientific Officer, Dr. June Lu. I will now turn the call over to our Chairman, Lan, please go ahead.

Thank you,[ Cedric ]. Good morning, everyone, and thank you for joining us today. First, let me briefly introduce BeyondSpring Inc., which was founded in 2010, is headquartered in New Jersey and was listed in NASDAQ in 2017. BeyondSpring holds an equity interest in Seed Therapeutics, which is a clinical stage molecular glue company with investments from global pharmaceutical companies, Eli Lilly and Eisai. In addition, we are developing a first-in-class anticancer small molecule agent, plinabulin, which has composition of matter patent protection through 2036 in over 40 jurisdictions with potential to extend to 2041 based on Hatch-Waxman rule.

Plinabulin has an extensive safety package. More than 700 cancer patients have been treated with plinabulin. We plan to initiate DUBLIN-4, a confirmative Phase III study in second-line/third-line non-squamous non-small cell lung cancer post immune checkpoint inhibitors, or ICI, 442-patient study with OS as the primary endpoint. We believe to this study to be supported by its unique mechanism and the previous encouraging clinical evidence. This is a patient population with significant unmet medical needs. Recently, 12 Phase III studies have failed to demonstrate an OS benefit over docetaxel, the current standard of care.

Plinabulin combined with docetaxel demonstrated OS benefit versus docetaxel in a Phase III study in non-small cell lung cancer, DUBLIN-3, which was published in the Lancet Respiratory Medicine in 2024. Learning from DUBLIN-3, we have designed DUBLIN-4 to focus on plinabulin mechanism-targeted non-small cell lung cancer patients. Today, we are excited to share with you the news that the FDA has granted Fast Track designation to plinabulin plus docetaxel for the patient population being studied in DUBLIN-4.

In addition, we entered into a strategic transaction to receive access to clinical data from around 50% of the 442 patients planned for DUBLIN-4 by selling our ownership in Greater China subsidiary. We believe this represents a more capital and execution-efficient path toward DUBLIN-4 interim analysis of 221 PFS events. After this strategic transaction, BeyondSpring still owns global rights of plinabulin outside of Greater China. Today, we would like to explain the scientific and the clinical rationale for DUBLIN-4, what the Fast Track designation means for this program and how the strategic transaction is expected to support this global Phase III study.

I will now turn the call over to our CEO, Min, to begin the presentation. Min, please go ahead.

Thank you, Lan. Good morning, everyone. As Lan mentioned, today, I will focus on 2 important developments for BeyondSpring and our DUBLIN-4 program, the FDA Fast Track designation and strategic transaction related to the China portion of DUBLIN-4. I will first outline the key messages, then turn the presentation over to June Lu, our Chief Scientific Officer, to review the unmet need, the mechanistic rationale for plinabulin and the clinical evidence supporting DUBLIN-4. After that, I will return to review the DUBLIN-4 study design and summarize the path forward for plinabulin and DUBLIN-4.

Let me begin with the key takeaway from today's update. We have 2 important developments that we believe strengthen the path forward for DUBLIN-4. First, the FDA has granted Fast Track designation for plinabulin plus docetaxel for the same patient population being studied in DUBLIN-4, second- and third-line non-squamous NSCLC following ICI treatment and platinum-based chemotherapy and without actionable genomic alterations. The designation provides opportunities for more frequent interaction with the FDA during development and may allow rolling review of a future regulatory application as well as potential eligibility for priority review if applicable criteria are met.

Second, we have entered into a strategic transaction involving the sale of our Greater China subsidiary interest to Biolin Investment Limited. Under this arrangement, BeyondSpring expects to receive access to clinical data from approximately 50% of the planned 442 patients in DUBLIN-4, supporting progress towards the study's interim analysis. Importantly, BeondSpring continues to retain the global rights to plinabulin outside Greater China. Together, these 2 developments are designed to improve the capital and execution efficiency of DUBLIN-4 and advance the study toward its next major clinical milestone, the prespecified interim analysis at 221 PFS events.

With that overview, I will now turn it over to June, our Chief Scientific Officer, to review the unmet need, the mechanistic rationale for plinabulin and the clinical evidence supporting DUBLIN-4. June, please go ahead.

Thank you, Min. I would like to expand on what Lan and Min just mentioned about the clinical need and the patient population that DUBLIN-4 is designed to address. Immune checkpoint inhibitors or ICI have become a major part of the standard of care for treatment of non-small cell lung cancer. However, almost 60% of the patients eventually progress after ICI treatment. For patients who do not have actionable genomic alteration, or commonly referred to as driver-negative, treatment options are limited once they progress after frontline ICI and platinum-based chemotherapy.

In this setting, docetaxel remains an important standard treatment option. However, historic outcomes with docetaxel remain modest with a median overall survival of approximately 9 to 11 months and significant hematologic toxicity, including over 40% severe neutropenia, which may limit docetaxel dose intensity and the treatment duration. Importantly, 12 Phase III studies using different treatment approaches, including 8 PD-1, PD-L1 inhibitor combinations and 4 antibody drug conjugate monotherapy in similar patient populations have failed to demonstrate an overall survival extension beyond docetaxel.

This highlights the significant unmet need in the post-ICI setting. Based on our projections, the post-ICI target population across the U.S. and the 5 major European markets of Germany, France, the United Kingdom, Italy and Spain could reach approximately 135,000 patients in 2037 at the projected peak sales if approved, which represents a meaningful patient population that DUBLIN-4 is designed to address. Before reviewing the clinical data, I would like to first highlight the mechanistic rationale for plinabulin in the post-ICI setting.

First is the structural basis of plinabulin as a first-in-class fast-off microtubule destabilizer with a distinct mechanism and a tolerability profile differentiated from other microtubule targeting agents on the market, such as taxanes, eribulin and vinca. Researchers now know that microtubules are not just structural elements of the cells, but also serve as dynamic sensors in response to stress signals. Plinabulin's interaction with microtubules triggers the release of guanine nucleotide exchange factor GEF-H1, a key signaling protein that drives dendritic cell, or DC maturation, antigen-presenting cell or APC activation and a subsequent antitumor immune response. This is especially the case when plinabulin is combined with standard of care chemotherapy or radiation that induces real-time tumor cell death and the release of tumor neoantigens. In other words, plinabulin's immune modulatory effect improves tumor antigen presentation that is necessary for sustained tumor-specific T-cell response to help overcome ICI resistance.

We have early clinical data that plinabulin also modulates tumor vasculature, which provides additional mechanistic rationale for going after non-squamous non-small cell lung cancer where anti-VEGF drugs are used. Finally, plinabulin has demonstrated neutropenia mitigating activity, which may help support chemotherapy dose intensity and the treatment continuity. Together, these complementary mechanisms provide a biological rationale for evaluating plinabulin containing regimens in the post-ICI setting. Let me now turn to the clinical evidence supporting this rationale. DUBLIN-4 is supported by encouraging clinical evidence from our DUBLIN-3 study together with the prospective data from Study 303.

First, in the overall DUBLIN-3 Phase III population of intention-to-treat 559 patients in second- and third-line EGFR wild-type non-small cell lung cancer with 1:1 randomization. Plinabulin plus docetaxel demonstrated a statistically significant overall survival benefit with a hazard ratio of 0.82. We also observed a long-term survival benefit with higher 24 and 36 months survival rates than docetaxel alone. Second, in the non-squamous population of 332 patients, which is more relevant to DUBLIN-4, the observed overall survival hazard ratio was 0.72 with a median extension of approximately 2.5 months.

Third, a post-hoc analysis of DUBLIN-3 revealed an encouraging efficacy signal in the post-ICI subgroup. The median overall survival was 15.8 months with plinabulin plus docetaxel compared to 11.7 months with docetaxel alone. The median progression-free survival or PFS was 5.6 months versus 3.8 months and the objective response rate or ORR was 18.2% versus 8%. In addition, Study 303 evaluated a plinabulin containing regimen with docetaxel in the post-ICI setting. It reported a median PFS of 7.0 months, an ORR of 18%, a disease control rate of approximately 80% and a 2-year overall survival rate of 58%.

These data suggests a more durable tumor response compared to docetaxel in similar patient populations as reported in TROPION-Lung01 and COSTAR Phase III study. Taken together, the DUBLIN-3 subgroup findings and the results from Study 303 provide a clinical rationale for evaluating DUBLIN-4 in a more clearly defined plinabulin mechanism-supported population of patients with non-squamous non-small cell lung cancer whose disease has progressed following ICI treatment.

With that, I will turn it back to Min to review the DUBLIN-4 study design and discuss how we plan to execute the program. Min, please go ahead.

Thank you, June. Let me now briefly review the design of DUBLIN-4. DUBLIN-4 is a confirmatory global Phase III study in post-ICI driver-negative non-squamous NSCLC. Approximately 442 patients are planned to be enrolled. Patients will be randomized 1:1 in the double-blind design. The experimental arm received docetaxel plus plinabulin, while the control arm received docetaxel plus placebo. OS is the primary endpoint with PFS, ORR and other important clinical and safety measures also included in the study. Approximately half of the planned enrollment is expected from China and approximately half from Western regions.

BeyondSpring brings several execution capabilities to this program, including global oncology and regulatory experience, experience completing Phase III studies and established clinical sites and investigator network and direct operational experience from DUBLIN-3. Our currently disclosed development timeline should start initiation around the end of 2026 to early 2027, with interim analysis expected in 2028. As interim analysis is event-driven, the timing will depend on enrollment and the accumulation of PFS events.

Let me close by bringing these elements together and highlighting what we believe creates a clear path to value creation for plinabulin. First, we have a differentiated clinical stage assets supported by a substantial body of scientific and clinical evidence. More than 700 cancer patients have been treated with plinabulin across multiple clinical programs, providing an extensive clinical safety database. In DUBLIN-3, plinabulin plus docetaxel demonstrated a statistically significant OS benefit and its differentiated GEF-H1 mechanism provides both immunomodulatory activity and the potential to mitigate chemotherapy-induced neutropenia.

Second, we believe DUBLIN-4 provides a focused path to confirm this clinical benefit in the mechanism targeted post-ICI non-squamous NSCLC population. Importantly, the FDA Fast Track designation and our strategic transaction related to the China portion of DUBLIN-4 are expected to strengthen both the regulatory and execution framework for the program. Based on our current development time line, the prespecified interim analysis is expected in 2028, subject to enrollment and the accumulation of the required PFS events.

Finally, we believe DUBLIN-4 addresses a large and underserved post-ICI NSCLC patient population and if successful, could establish a meaningful commercial opportunity for plinabulin and unlock plinabulin's potential as a differentiated anticancer agent in NSCLC and beyond. Taken together, we believe the clinical evidence, differentiated mechanism, focused Phase III strategy and recent regulatory and strategic developments provide a clear path towards the next major value-creating milestones for plinabulin and BeyondSpring. Our focus now is on disciplined execution of DUBLIN-4 and advancing the program towards its prespecified interim analysis. With that, I will turn the call back to Lan.

Thank you, Min, and thank you, June. We believe these developments represent important progress for BeyondSpring and DUBLIN-4. We remain focused on executing the global Phase III program and advancing plinabulin towards its next major clinical milestone. With that, we're ready to take your questions. Operator, please open the line for Q&A.

[Operator Instructions] Our first question is from the line of Silvan Tuerkcan with Citizens.

Congrats on the transaction and the update here. Maybe just starting off big picture here. As you highlighted, there's 12 Phase III studies that showed no OS benefit, which points to the really big unmet need here post checkpoint inhibitors. Could you just maybe summarize one more time why DUBLIN-4 should work? And specifically, how did your prior observations and insights on the mechanism inform the trial? And how did you get to your powering assumptions from DUBLIN-3 and the Study 303? And then I have a follow-up.

Yes. Thank you, Silvan. I think I'm going to turn the answers to Dr. June Lu, our CSO.

Yes. Thank you for the question. This is June Lu. Yes, I agree with you that given the type of data out there, this is a challenging therapeutic space competing against docetaxel in post-ICI setting. I should also mention that in the recent COSTAR Lung Phase III study, Jemperli or dostarlimab plus docetaxel did not surpass docetaxel in PFS and overall survival. But still, this space is very active with at least 8 Phase III studies either ongoing or not yet recruiting, evaluating novel IO agent, ADCs, including those of novel targets bispecific antibody or bispecific ADC.

So to our end, we believe that plinabulin's mechanism supports the DUBLIN-4 program as the following: First, as docetaxel kills the cancer cells in the body, plinabulin is there to drive immunogenic DC maturation, breaking the immune tolerance, which is the key determinant to fully reverse T-cell exhaustion. We also stacked the deck in our favor, so to speak, by enrolling only non-squamous patients based on the efficacy data we saw in DUBLIN-3, Study 303 in post-ICI non-small cell lung cancer patients and the tumor vasculature effect of plinabulin. Together with the CIN benefit of plinabulin that allows for more docetaxel dosing and a better bone marrow recovery, we think that plinabulin helps to refresh and sustain the cancer immunity cycle for more durable antitumor immune response to help overcome IO resistance. Lan please chime in.

Yes. Thank you, June. Yes, Silvan, you asked this great question. So we have been studying plinabulin for over 15 years in its immune modulating mechanism. And we believe that it's differentiated DC maturation and also targeting vasculature and finally, reducing chemotherapy neutropenia really is perfect to combine this profile for this -- to get into this DUBLIN-4 population. And from the study design and also patient number, we have worked with independent statistician to use the DUBLIN-3 study data and also the OS hazard ratio for non-squamous population and also the post-hoc analysis in ICI progression patients to determine this 442-patient 1:1 randomization with a power of over 85%. Yes.

Yes. Great. And maybe on the business side, did the FDA sign off on your DUBLIN-4 basically design and maybe the patient composition, right? So now you will have a significant number of Chinese patients and then rest of world patients. Did they sign up for it and specifically the 50-50 split that you can expect here in this trial?

So Yes, if I can just start and then Min can chime in into the split of Western and Asian population split. So from a study design point of view, our Phase III protocol for DUBLIN-4 has been aligned with FDA in this population and also OS is the primary endpoint. And we are very honored to receive the Fast Track designation from FDA for this population. So secondly is, of course, it's always good to have more Western patients. But depending on where the patients come from the speed and also cost efficiency and also the support for the global study and the package for the FDA approval, where to utilize this 50-50 split. And they already have some examples before for this successful regulatory strategy. Min, you can talk about those examples.

Thank you, Silvan. Thank you, Lan. Yes, of course, there are also recent FDA approvals supported by programs with a substantial proportion of Asian patients. For example, the Nuvation Bio's drug taletrectinib, was approved based in part on the study conducted entirely in China together with the global study that also enrolled a high proportion of Asian patients. And also a drug from Dizal called sunvozertinib was approved based on a multinational study in which approximately 65% of the efficacy population was Asian.

But I think which is most important for us is that DUBLIN-4 will apply the same protocol and evaluation standards across regions. PK and efficacy will be evaluated across Asian and Western populations to assess the consistency of drug exposure and treatment effect. So yes, I think we believe our approximately 50-50 strategy is reasonable. Yes, of course, the ultimate acceptability of the data will depend on the actual study results and FDA's review. Thank you.

[Operator Instructions] The next question is a follow-up from the line of Silvan Tuerkcan with Citizens.

Yes. One more question, if I may be able to sneak that in. After obviously, this transaction that you just did, how much -- can you just maybe summarize your cash needs and how that aligns with the time in operations and trial start-up costs in the U.S. versus your first interim analysis in 2028?

Yes. So probably I can start, and then Min can chime in. So as you see that this study is a 442-patient study with the prespecified interim at a 221 PFS event. So with this very important noncash and also non-dilutive transaction with investors, that we are getting around 50% of the patient data, which is around 221 PFS events and OS events in the future. So that definitely cuts down on the cost for the -- for BeyondSpring to generate data to get to the prespecified interim analysis, which is the 221 PFS events. So the actual how much to be saved, of course, it's going to be determined by the study operation. But as you see here, already more than half of the study cost is reduced. And also China has such a great population of non-small cell lung cancer patients. So the speed is also going to add to our arrival at the prespecified interim analysis. Thank you for the great question.

Great. And sorry, one last one, if I may. So obviously, this is a small molecule, but it seems to do a lot of things. Maybe can you just summarize how, I guess, the mechanism of GEF-H1, kind of, explains all of these? And how does that line up with some of the side effects that you've seen in DUBLIN-3, such as the GI side effects and the hypertension?

Yes. So June will comment.

Yes. I very much welcome this in-depth question. We have been -- as Lan mentioned, we have been building our knowledge base over the years. First, I want to mention that people only recently recognized the sensory role of microtubules that may be as important or more important than their traditional architectural role. According to a recent Cell paper published by our collaborator, Dr. Michelle Steinmetz at the University of Basel, GEF-H1 is one of the key microtubule associated signaling proteins, but there are others that are not yet explored.

Second is GEF-H1 function is different in different cell types. Obviously, microtubules are everywhere, right? So biologically, its activity is highly regulated through phosphorylation sites depending on the timing, location and environmental cure. Under myelosuppressive condition, the bone marrow recovery or regenerative hematopoiesis is also a GEF-H1 dependent process. As far as the side effect you mentioned, GEF-H1 regulates barrier integrity in the intestine and normal vasculature.

The GI side effect is managed in the clinic by medication. We actually consulted with Dr. Christine Reinecker at UT Southwestern, who specializes in gastroenterology and gut health. He published in April this year that a long isoform of GEF-H1 is located in intestinal epithelial cells. So he believes that plinabulin's GI side effect may attribute to that. As far as the hypertension, the hypertension is transient, which often resolves within 4 to 6 hours after infusion. This is because GEF-H1 is at the tight juncture that its minor disturbance can cause transient endothelial disturbance shift. So I hope that answers your question.

And congrats again on the update.

At this time, I'll hand the floor back to Min for closing comments.

Yes. Thank you. Thank you for your questions and for joining us today. We appreciate your continued interest in BeyondSpring. We look forward to keeping you updated as we advance DUBLIN-4 and the development of plinabulin to help patients with high unmet medical need. Thank you, and have a good day.

Thank you. This will conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.